Psyence Biomedical Settles Shareholder Dispute With KAOS Capital
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Psyence Biomedical ( (PBM) ) has shared an announcement.
On February 9, 2026, Psyence Biomedical Ltd. entered into a settlement agreement with KAOS Capital Ltd. and related parties to resolve a direct shareholder claim filed in the Ontario Superior Court, following allegations first raised in January 2026. The company, which has consistently denied the accusations, had previously secured a court dismissal of KAOS’s application on January 21, 2026, along with a costs award in its favor.
Under the settlement, Psyence will pay KAOS a total of US$1.5 million, waive the C$75,000 costs award, and arrange for a third party to purchase KAOS’s 50,220 common shares at US$5 per share. KAOS will fully retract its unproven allegations, both sides will grant mutual releases, and Psyence expects to fund the payout from cash on hand, positioning the deal as a way to avoid further litigation costs and operational disruption while drawing a line under a contentious shareholder dispute.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a Nasdaq-listed, multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. It focuses on developing nature-derived, non-synthetic psilocybin and ibogaine-based medicines aimed at addressing unmet mental health needs through evidence-based, regulatory-approved treatments.
Average Trading Volume: 355,023
Technical Sentiment Signal: Sell
Current Market Cap: $3.25M
For detailed information about PBM stock, go to TipRanks’ Stock Analysis page.
